Just more than one year after it was created, the office of Women Faculty Programs at The University of Texas M. D. Anderson Cancer Center has introduced a collection of essays by leading women faculty aimed at inspiring generations of women scientists to come.
Since its launch in 16 states this past November, The University of Texas M. D. Anderson Cancer Center has graduated 250 students and enrolled another 1,707 via its ASPIRE anti-tobacco program deployed in school districts across the country.
The European Commission, which oversees legislation and regulation for the European Union, has approved a therapy for pediatric patients with non-metastatic, resectable osteosarcoma, a type of bone cancer. The approval is based on clinical studies led by researchers at The University of Texas M. D. Anderson Cancer Center and a national co-operative group.
Researchers have crafted a gene circuit that permits precise tuning of a gene's expression in a cell, an advance that should allow for more accurate analysis of the gene's role in normal and abnormal cellular function.
Women at increased risk for breast cancer because of the genetic BRCA mutations are more likely to think a prophylactic mastectomy is the best way to reduce their risk for the disease, compared to other women who are at high risk, according to researchers at The University of Texas M. D. Anderson Cancer Center.
Today, patients have a wide selection of colorectal cancer screening exams from which to choose, unlike with other types of cancers. Experts at The University of Texas M. D. Anderson Cancer Center provide insight on the two most talked about tests, colonoscopy and virtual colonoscopy.
A receptor known to be active in bone metastases, but previously unexplored in primary bone tumors, is a potential therapeutic target in osteosarcoma, investigators from The University of Texas M. D. Anderson Cancer Center report in the March 1 issue of Cancer Research.
Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have created a device that significantly decreases the time needed to produce genetically manipulated T cells in preclinical tests for leukemia.
Illuminating the molecular details of normal sperm development, demonstrating how chemotherapy or radiation can leave a man or boy sterile, and pursuing ways to restore fertility have earned a major honor for a scientist at The University of Texas M. D. Anderson Cancer Center.
Young women who develop breast cancer during their pregnancy, or who are diagnosed within one year of their pregnancy, have no difference in rates of local recurrence, distant metastases and overall survival compared to other young women with the disease, according to researchers at The University of Texas M. D. Anderson Cancer Center.
Researchers from The University of Texas M. D. Anderson Cancer Center have found that increased angiogenesis, or blood vessel formation, and vascular endothelial growth factor expression are associated with poor survival in women with sex cord-stromal ovarian tumors. This data was presented in a poster session today at the Society of Gynecologic Oncologists' 40th Annual Meeting on Women's Cancer.
"The great news this Valentine's Day is that in addition to being decadent and delicious, moderate amounts of dark chocolate may play a role in cancer prevention," said Sally Scroggs, M.S., R.D., L.D., health education manager at The University of Texas M. D. Anderson Cancer Center's Cancer Prevention Center.
Hollow gold nanospheres equipped with a targeting peptide find melanoma cells, penetrate them deeply, and then cook the tumor when bathed with near-infrared light, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reported in the Feb. 1 issue of Clinical Cancer Research.
A preventive procedure to remove the unaffected breast in breast cancer patients with disease in one breast may only be necessary in patients who have high-risk features as assessed by examining the patient's medical history and pathology of the breast cancer, according to researchers at The University of Texas M. D. Anderson Cancer Center.
Bacteria hunker down and survive antibiotic attack when a protein flips a chemical switch that throws them into a dormant state until treatment abates, researchers at The University of Texas M. D. Anderson Cancer Center report in the Jan.16 edition of Science.
Abnormalities in genes that repair mistakes in DNA replication may help identify people who are at high risk of developing pancreatic cancer, a research team from The University of Texas M. D. Anderson Cancer Center reports in the Jan. 15 issue of Clinical Cancer Research.
Variations in mismatch repair genes can help predict treatment response and prognosis in patients with pancreatic cancer, according to research from The University of Texas M. D. Anderson Cancer Center presented today in advance of the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.
January is Cervical Cancer Awareness Month and The University of Texas M. D. Anderson Cancer Center shares important information about the cervical cancer screening exam, the Pap test.
A tumor-suppressing gene is a key to understanding, and perhaps killing, dormant ovarian cancer cells that persist after initial treatment only to reawaken later, researchers at The University of Texas M. D. Anderson Cancer Center report. They found that expression of ARHI turns on autophagy, or self-eating, in ovarian cancer cells, which promotes their survival in a dormant state
Amy Heimberger, M.D., associate professor of neurosurgery at The University of Texas M. D. Anderson Cancer Center has received a Presidential Early Career Award for Scientists and Engineers (PECASE), in recognition for her research on the central nervous system's immune biology, tumor evasion of immune detection and immunotherapeutic approaches for patients with malignant gliomas.
Levels of two proteins in a woman's ovarian cancer are strongly associated with her likelihood of survival, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Dec. 18 issue of the New England Journal of Medicine.
Lorenzo Cohen, Ph.D., Director of the Integrative Medicine Program at The University of Texas M. D. Anderson Cancer Center is the recipient of the 2007 International Scientific and Technological Cooperation Award of Shanghai Municipality (ISTCASM) and the 2008 Magnolia Memorial Award for his contributions in furthering research into the use of traditional Chinese medicine in cancer therapies.
Magnetic resonance imaging (MRI) alternated with mammography at six-month intervals can detect breast cancers not identified by mammography alone, a research team from The University of Texas M. D. Anderson Cancer Center will report at the 31st at the CRTC-AACR San Antonio Breast Cancer Symposium.
Expression of the microtubule-binding protein Tau is not a reliable means of selecting breast cancer patients for adjuvant paclitaxel chemotherapy, according to research led by The University of Texas M. D. Anderson Cancer Center.
Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.
Findings from one of the largest cancer chemoprevention trials ever conducted have concluded that selenium and vitamin E taken alone or in combination for an average of five and a half years did not prevent prostate cancer, according to a team of researchers coordinated by the Southwest Oncology Group (SWOG) and led by scientists at The University of Texas M. D. Anderson Cancer Center and Cleveland Clinic.
Patients respond well to a new three-drug combination for indolent B cell lymphoma that also spares them prolonged, potentially lethal, suppression of blood production in the bone marrow, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.
More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.
A new risk model for myelodysplastic syndrome provides survival projections that apply to patients at any stage of the disease, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th Annual Meeting of the American Society of Hematology.
Two drugs approved as fallback therapy for chronic myelogenous leukemia (CML) appear to outperform historical benchmarks of the frontline medication when used as a first treatment in separate clinical trials, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 50th Annual Meeting of the American Hematological Society.
Taking blood stem cells collected from an umbilical cord into the lab and expanding their number before transplanting them to replace a patient's blood supply is as safe as a standard cord blood transplant, researchers reported today at the 50th Annual Meeting of the American Society of Hematology.
The oral medication lenalidomide is safe and well-tolerated for elderly patients with chronic lymphocytic leukemia, a group without a well-defined frontline therapy for their disease, researchers from The University of Texas M. D. Anderson Cancer Center reported today.
Patients older than 65 do just as well as younger patients with transplants that are preceded by a milder chemotherapy regimen, according to an intensive analysis of every such transplant for AML or MDS conducted in North America between 1995-2005. The analysis also included international transplant data.
The University of Texas M. D. Anderson Cancer Center will hold the first international inflammatory breast cancer (IBC) conference on December 6-7, to bring together internationally recognized breast cancer clinicians and scientists.
Margaret Spitz, M.D., professor and former chair of at The University of Texas M. D. Anderson Cancer Center, is one of eight distinguished inductees into the inaugural Greater Houston Women's Chamber of Commerce (GHWCC) Hall of Fame.
A new species of bacterium that causes leprosy has been identified through intensive genetic analysis of a pair of lethal infections, a research team reports in the December issue of the American Journal of Clinical Pathology.
The University of Texas M. D. Anderson Cancer Center marked the beginning of a collaborative effort to eradicate breast cancer in Panama through the Partnership for Breast Cancer Awareness and Research of the Americas today at an event with Laura Bush, the First Lady of the United States, and Vivian Fernández de Torrijos, the First Lady of Panama.
Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center.
In the wake of the nation's historic presidential election, political commentators Mary Matalin and James Carville will put aside their party differences Dec. 9 in Houston to raise funds for cancer research and patient care programs at The University of Texas M. D. Anderson Cancer Center. Matalin and Carville will be interviewed by veteran ABC News correspondent Sam Donaldson at "A Conversation With a Living Legend" from 11:30 a.m. - 1:30 p.m. at the Hilton Americas Hotel.
A home-based program to improve exercise and diet led to significant, clinically meaningful improvement in body weight and physical function among older long-term cancer survivors in preliminary findings from the RENEW (Reach-out to ENhancE Wellness) trial, according to Wendy Demark-Wahnefried, Ph.D., from The University of Texas M. D. Anderson Cancer Center's Department of Behavioral Science. The data are being presented at the seventh annual American Association for Cancer Research Frontiers in Cancer Prevention Conference.
The University of Texas M. D. Anderson Cancer Center, one of 12 cancer centers in the Cancer Research Alliance (CRA), and Mall Networks, the leading provider of merchant-funded loyalty shopping solutions, today announced the launch of a new online shopping mall to raise money for cancer research and patient care programs.
A protein known to inhibit the growth of ovarian cancer works in part by forcing cancer cells to eat themselves until they die, researchers at The University of Texas M. D. Anderson Cancer Center report in the Nov. 15 issue of Cancer Research.
Patients treated for locally advanced non-small cell lung cancer who receive chemotherapy and proton beam therapy have fewer instances of bone marrow toxicity than patients who receive the standard treatment of intensity-modulated radiation (IMRT) and concurrent chemotherapy, according to researchers from The University of Texas M. D. Anderson Cancer Center.
The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center.
Variations in a common gene pathway may affect esophageal cancer risk, a dangerous and rapidly increasing type of cancer, according to research by scientists at The University of Texas M. D. Anderson Cancer Center.
AstraZeneca and The University of Texas M. D. Anderson Cancer Center today announced they have renewed their collaboration to integrate pre-clinical and clinical research with a view to speeding up access to new medicines of potential benefit to cancer patients.
The drug tamoxifen does not prevent or treat estrogen receptor (ER) negative breast cancer, but it can make the disease easier to find, researchers report in the Oct. 1 Journal of the National Cancer Institute.
A multi-institutional study led by researchers at The University of Texas M. D. Anderson Cancer Center has found that using chemotherapy alone and delaying or avoiding cranial radiation altogether can be effective in treating pediatric patients with unresectable or progressive low-grade glioma. The study was presented Sunday at the 40th annual International Society of Pediatric Oncology Meeting in Berlin, Germany.
The National Cancer Institute (NCI) has renewed The University of Texas M. D. Anderson Cancer Center's Cancer Center Support Grant, an essential step in extending the institution's elite status as a comprehensive cancer center.
The University of Texas M. D. Anderson Cancer Center has received nearly $19 million in grants from Susan G. Komen for the Cure as part of that organization's new initiative to fast-track promising research to benefit breast cancer patients.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right